Summary of patient baseline clinical and imaging characteristicsa
| Lidocaine (n = 175) | Corticosteroid and Lidocaine (n = 175) | |
|---|---|---|
| Patient demographics | ||
| Female | 53% (93/175) | 57% (100/175) |
| Age range; mean (SD) | 50–96; 68 (9.9) | 50–89; 68 (9.6) |
| Baseline clinical measures | ||
| RDQ disability score | 15.6 (4.3) | 16.1 (4.5) |
| Leg pain NRS | 7.2 (1.7) | 7.1 (1.9) |
| Back pain NRS | 6.6 (2.6) | 6.6 (2.4) |
| Mean of leg and back pain NRS | 6.6 (1.2) | 6.5 (1.5) |
| SSSQ symptom subscale score | 3.1 (0.6) | 3.2 (0.6) |
| SSSQ physical function subscale score | 2.5 (0.5) | 2.5 (0.5) |
| Injection characteristics | ||
| Interlaminar approach | 68% (119/175) | 69% (120/175) |
| Transforaminal approach | 32% (56/175) | 31% (55/175) |
| Mean lumbar level distance from injection to level of qualitative worst stenosis | 0.6 (0.6) | 0.5 (0.7) |
| Qualitative CT and MRI | n = 175 | n = 175 |
| Measures | ||
| Maximum qualitative central stenosis | 2.2 (0.8) | 2.3 (0.9) |
| Mean qualitative central stenosis | 1.2 (0.4) | 1.2 (0.5) |
| Qualitative MRI measures | n = 150 | n = 158 |
| Maximum qualitative CSF effacement | 2.0 (1.1) | 2.0 (1.1) |
| Mean qualitative CSF effacement | 0.7 (0.6) | 0.7 (0.6) |
| Quantitative MRI measures | n = 148 | n = 156 |
| Minimum thecal sac cross-sectional area (mm2) | 72 (38) | 73 (39) |
| Mean thecal sac cross-sectional (mm2) | 130 (40) | 130 (38) |
| Minimum thecal sac AP diameter on axial images (mm) | 7.2 (2.5) | 7.2 (2.4) |
| Mean thecal sac AP diameter on axial images (mm) | 10.6 (2.0) | 10.5 (2.0) |
| Minimum thecal sac AP diameter on sagittal images (mm) | 6.2 (2.3) | 6.4 (2.4) |
| Mean thecal sac AP diameter on sagittal images (mm) | 9.5 (2.0) | 9.6 (2.0) |
| Minimum thecal sac ML diameter (mm) | 11.6 (3.2) | 11.6 (3.1) |
| Mean thecal sac ML diameter (mm) | 16.1 (2.7) | 16.1 (2.5) |
Note:—SSSQ indicates Swiss Spinal Stenosis Questionnaire.
↵a Values represent mean and SD unless otherwise specified.